# Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.

> **NCT00933517** · PHASE2 · COMPLETED · sponsor: **Centre Jean Perrin** · enrollment: 62 (actual)

## Conditions studied

- Pathological Response Rate

## Interventions

- **DRUG:** vectibix
- **DRUG:** fluorouracile
- **DRUG:** Epirubicine
- **DRUG:** cyclophosphamide
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00933517
- **Lead sponsor:** Centre Jean Perrin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2014-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00933517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00933517, "Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00933517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*